November 25, 2016 - By Marie Mckinney
In a analysts note shared with investors and clients on 25 November, Suntrust Robinson has decreased Juno Therapeutics Inc (NASDAQ:JUNO) stock to a “Hold” and has set a 12-month price target at $25.00. JUNO’s old rating was “Buy”.
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. $73 is the highest target while $30 is the lowest. The $47.10 average target is 108.87% above today’s ($22.55) stock price. Juno Therapeutics Inc has been the topic of 20 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Friday, August 5 by Maxim Group. Standpoint Research initiated it with “Buy” rating and $47.0 target price in Monday, August 24 report. The rating was initiated by Citigroup with “Buy” on Thursday, February 25. The rating was initiated by Raymond James with “Outperform” on Thursday, June 2. Suntrust Robinson initiated Juno Therapeutics Inc (NASDAQ:JUNO) on Friday, January 29 with “Buy” rating. The rating was downgraded by Standpoint Research to “Hold” on Thursday, October 29. Northland Capital initiated the stock with “Outperform” rating in Wednesday, July 22 report. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Equal-Weight” rating given on Wednesday, July 6 by Barclays Capital. On Wednesday, November 23 the stock rating was downgraded by FBR Capital to “Mkt Perform”. FBR Capital maintained Juno Therapeutics Inc (NASDAQ:JUNO) on Friday, July 8 with “Outperform” rating.
About 16,522 shares traded hands. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 49.28% since April 22, 2016 and is downtrending. It has underperformed by 54.69% the S&P500.
Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 EPS, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual EPS reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.
Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.06, from 1.34 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Teachers Advisors holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 52,548 shares. Tekla Capital Management Limited Liability Co holds 182,000 shares or 0.29% of its portfolio. Point72 Asia (Hong Kong) Ltd accumulated 100 shares or 0% of the stock. Susquehanna Grp Limited Liability Partnership holds 101,172 shares or 0% of its portfolio. Teacher Retirement Of Texas holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 6,475 shares. Benjamin F Edwards & Co last reported 2,960 shares in the company. Temasek (Private) Ltd holds 0.28% or 915,750 shares in its portfolio. Tocqueville Asset L P has 0.02% invested in the company for 34,200 shares. Evercore Wealth Management Ltd Liability Company owns 18,937 shares or 0.03% of their US portfolio. Moreover, Winfield Assocs Inc has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 20 shares. Tiaa Cref Investment Mngmt Limited Com holds 323,062 shares or 0.01% of its portfolio. Allianz Asset Mgmt Ag accumulated 165,250 shares or 0% of the stock. Springbok Cap Management Limited has 500 shares for 0% of their US portfolio. Guggenheim Ltd owns 115,404 shares or 0.01% of their US portfolio. State Street Corporation has 0.01% invested in the company for 1.66M shares.
Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $1.80 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
More important recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Why Juno Therapeutics Inc Plummeted Today” on November 23, 2016, also Marketwatch.com published article titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …”, Fool.com published: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” on November 03, 2016. More interesting news about Juno Therapeutics Inc (NASDAQ:JUNO) was released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: Caleres Rises On Earnings Beat; Juno Therapeutics …” with publication date: November 23, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.